Poolbeg Pharma #POLB – AI programme yields novel RSV drug targets March 29, 2022 – Posted in: Poolbeg Pharma (POLB)
AI programme yields novel RSV drug targets Artificial intelligence programme yields multiple novel RSV drug targets First time AI has been used to identify disease targets in RSV 8 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial Intelligence (‘AI’) Programme with partner OneThree Biotech , Inc. through…
Continue reading